160 related articles for article (PubMed ID: 25968921)
1. Involvement of CYP 3A5 In the Interaction Between Tacrolimus and Nicardipine: A Case Report.
Sassi MB; Gaies E; Salouage I; Trabelsi S; Lakhal M; Klouz A
Curr Drug Saf; 2015; 10(3):254-6. PubMed ID: 25968921
[TBL] [Abstract][Full Text] [Related]
2. Risk of tacrolimus toxicity in CYP3A5 nonexpressors treated with intravenous nicardipine after kidney transplantation.
Hooper DK; Fukuda T; Gardiner R; Logan B; Roy-Chaudhury A; Kirby CL; Vinks AA; Goebel J
Transplantation; 2012 Apr; 93(8):806-12. PubMed ID: 22491658
[TBL] [Abstract][Full Text] [Related]
3. Comparative clinical trial of the variability factors of the exposure indices used for the drug monitoring of two tacrolimus formulations in kidney transplant recipients.
Marquet P; Albano L; Woillard JB; Rostaing L; Kamar N; Sakarovitch C; Gatault P; Buchler M; Charpentier B; Thervet E; Cassuto E
Pharmacol Res; 2018 Mar; 129():84-94. PubMed ID: 29229354
[TBL] [Abstract][Full Text] [Related]
4. Polymorphism of the CYP3A5 gene and its effect on tacrolimus blood level.
Nair SS; Sarasamma S; Gracious N; George J; Anish TS; Radhakrishnan R
Exp Clin Transplant; 2015 Apr; 13 Suppl 1():197-200. PubMed ID: 25894154
[TBL] [Abstract][Full Text] [Related]
5. Metabolism of tacrolimus (FK506) and recent topics in clinical pharmacokinetics.
Iwasaki K
Drug Metab Pharmacokinet; 2007 Oct; 22(5):328-35. PubMed ID: 17965516
[TBL] [Abstract][Full Text] [Related]
6. Increased hospital stay and allograft dysfunction in renal transplant recipients with Cyp2c19 AA variant in SNP rs4244285.
Bosó V; Herrero MJ; Bea S; Galiana M; Marrero P; Marqués MR; Hernández J; Sánchez-Plumed J; Poveda JL; Aliño SF
Drug Metab Dispos; 2013 Feb; 41(2):480-7. PubMed ID: 23175667
[TBL] [Abstract][Full Text] [Related]
7. Supra-therapeutic tacrolimus concentrations associated with concomitant nicardipine in pediatric liver transplant recipients.
Hurst AL; Clark N; Carpenter TC; Sundaram SS; Reiter PD
Pediatr Transplant; 2015 Jun; 19(4):E83-7. PubMed ID: 25850753
[TBL] [Abstract][Full Text] [Related]
8. Which Genetic Determinants Should be Considered for Tacrolimus Dose Optimization in Kidney Transplantation? A Combined Analysis of Genes Affecting the CYP3A Locus.
Bruckmueller H; Werk AN; Renders L; Feldkamp T; Tepel M; Borst C; Caliebe A; Kunzendorf U; Cascorbi I
Ther Drug Monit; 2015 Jun; 37(3):288-95. PubMed ID: 25271728
[TBL] [Abstract][Full Text] [Related]
9. Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus.
Hesselink DA; van Schaik RH; van der Heiden IP; van der Werf M; Gregoor PJ; Lindemans J; Weimar W; van Gelder T
Clin Pharmacol Ther; 2003 Sep; 74(3):245-54. PubMed ID: 12966368
[TBL] [Abstract][Full Text] [Related]
10. Tacrolimus Dose Optimization Strategy for Refractory Ulcerative Colitis Based on the Cytochrome P450 3A5 Polymorphism Prediction Using Trough Concentration after 24 Hours.
Onodera M; Endo K; Naito T; Moroi R; Kuroha M; Kanazawa Y; Kimura T; Shiga H; Kakuta Y; Negoro K; Kinouchi Y; Shimosegawa T
Digestion; 2018; 97(1):90-96. PubMed ID: 29393157
[TBL] [Abstract][Full Text] [Related]
11. Impact of CYP3A5 polymorphism on trough concentrations and outcomes of tacrolimus minimization during the early period after kidney transplantation.
Yaowakulpatana K; Vadcharavivad S; Ingsathit A; Areepium N; Kantachuvesiri S; Phakdeekitcharoen B; Sukasem C; Sra-Ium S; Sumethkul V; Kitiyakara C
Eur J Clin Pharmacol; 2016 Mar; 72(3):277-83. PubMed ID: 26635230
[TBL] [Abstract][Full Text] [Related]
12. CYP3A pharmacogenetics and tacrolimus disposition in adult heart transplant recipients.
Deininger KM; Vu A; Page RL; Ambardekar AV; Lindenfeld J; Aquilante CL
Clin Transplant; 2016 Sep; 30(9):1074-81. PubMed ID: 27314545
[TBL] [Abstract][Full Text] [Related]
13. Combinational Effect of CYP3A5 and MDR-1 Polymorphisms on Tacrolimus Pharmacokinetics in Liver Transplant Patients.
Buendía JA; Otamendi E; Kravetz MC; Cairo F; Ruf A; de Davila M; Powazniak Y; Nafissi J; Lazarowski A; Bramuglia G; Villamil F
Exp Clin Transplant; 2015 Oct; 13(5):441-8. PubMed ID: 26450467
[TBL] [Abstract][Full Text] [Related]
14. CYP3A5 and CYP3A4 but not MDR1 single-nucleotide polymorphisms determine long-term tacrolimus disposition and drug-related nephrotoxicity in renal recipients.
Kuypers DR; de Jonge H; Naesens M; Lerut E; Verbeke K; Vanrenterghem Y
Clin Pharmacol Ther; 2007 Dec; 82(6):711-25. PubMed ID: 17495880
[TBL] [Abstract][Full Text] [Related]
15. The combination of CYP3A4*22 and CYP3A5*3 single-nucleotide polymorphisms determines tacrolimus dose requirement after kidney transplantation.
Lloberas N; Elens L; Llaudó I; Padullés A; van Gelder T; Hesselink DA; Colom H; Andreu F; Torras J; Bestard O; Cruzado JM; Gil-Vernet S; van Schaik R; Grinyó JM
Pharmacogenet Genomics; 2017 Sep; 27(9):313-322. PubMed ID: 28704257
[TBL] [Abstract][Full Text] [Related]
16. Effects of CYP3A5 polymorphism on the pharmacokinetics of a once-daily modified-release tacrolimus formulation and acute kidney injury in hematopoietic stem cell transplantation.
Yamashita T; Fujishima N; Miura M; Niioka T; Abumiya M; Shinohara Y; Ubukawa K; Nara M; Fujishima M; Kameoka Y; Tagawa H; Hirokawa M; Takahashi N
Cancer Chemother Pharmacol; 2016 Jul; 78(1):111-8. PubMed ID: 27217047
[TBL] [Abstract][Full Text] [Related]
17. Associations of HSD11B1 polymorphisms with tacrolimus concentrations in Chinese renal transplant recipients with prednisone combined therapy.
Liu X; Li J; Fu Q; Liu S; Zhang Y; Wang X; Wang H; Li J; Zhu C; Wang C; Huang M
Drug Metab Dispos; 2015 Apr; 43(4):455-8. PubMed ID: 25587129
[TBL] [Abstract][Full Text] [Related]
18. Influence of combined CYP3A4 and CYP3A5 single-nucleotide polymorphisms on tacrolimus exposure in kidney transplant recipients: a study according to the post-transplant phase.
Aouam K; Kolsi A; Kerkeni E; Ben Fredj N; Chaabane A; Monastiri K; Boughattas N
Pharmacogenomics; 2015 Dec; 16(18):2045-54. PubMed ID: 26615671
[TBL] [Abstract][Full Text] [Related]
19. Drug interaction between tacrolimus and ertapenem in renal transplantation recipients.
Bora F; Aliosmanoglu I; Kocak H; Dinckan A; Uslu HB; Gunseren F; Suleymanlar G
Transplant Proc; 2012 Dec; 44(10):3029-32. PubMed ID: 23195020
[TBL] [Abstract][Full Text] [Related]
20. Impact of the CYP3A5*1 Allele on the Pharmacokinetics of Tacrolimus in Japanese Heart Transplant Patients.
Uno T; Wada K; Matsuda S; Terada Y; Oita A; Kawase A; Takada M
Eur J Drug Metab Pharmacokinet; 2018 Dec; 43(6):665-673. PubMed ID: 29691732
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
